However, despite AAT inhibition of α-defensins signaling, we know that AATD individuals with frequent exacerbations phenotype continue to have recurrent infections and lung function decline even on augmentation therapy. Here, SERPINA1 is linked to alpha 1-antitrypsin deficiency.